Content about Reddy

October 25, 2011
Sales, profits increase for Dr. Reddy's in Q2

Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

HYDERABAD, India — Dr. Reddy's Labs reported sales of $462 million for second quarter 2012 and $866 million for the first half of the fiscal year, according to an earnings statement released Tuesday.

The Indian generic drug maker said the second-quarter sales represented a 21% increase over second quarter 2011. Sales from global generics were $329 million for the quarter, an 18% increase over second quarter 2011, driven mostly by growth in North America and Russia.

Profits for the quarter were $63 million, a 7% increase over second quarter 2011.

October 19, 2011
ReportersNotebook — Chain Pharmacy, 10/24/11

The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO’s drugs by the end of the decade.

SUPPLIER NEWS — The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO’s drugs by the end of the decade. The drug makers announced the settlement in the U.S. District Court for the District of Delaware, whereby Teva can launch a generic version of the injectable anticoagulant drug Angiomax (bivalirudin) in June 2019.


September 22, 2011
Dr. Reddy's launches generic Alzheimer's drug

Dr. Reddy's Labs has launched a drug for treating Alzheimer's disease, the company said.

NEW YORK — Dr. Reddy's Labs has launched a drug for treating Alzheimer's disease, the company said.

Dr. Reddy's announced the launch of rivastigmine tartrate capsules in the 1.5-mg, 3-mg, 4.5-mg and 6-mg strengths.

The drug is a generic version of Novartis' Exelon. Exelon and other generic versions of the drug had sales of about $92.6 million during the 12-month period ended in June, according to IMS Health.

September 1, 2011
Dr. Reddy's, Pfizer settle over Lipitor

Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

NEW YORK — Pfizer and Dr. Reddy's have reached a settlement over the latter's efforts to launch a generic version of the world's top-selling drug, according to published reports.

August 30, 2011
Dr. Reddy's to field Allegra-D store-brand equivalent

Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

HYDERABAD, India — Dr. Reddy’s Labs on Tuesday announced that it has launched its over-the-counter fexofenadine and pseudoephedrine extended-release tablets.

Dr. Reddy’s will market the product, the equivalent to Allegra-D 24 Hour, under store-brand labels in the U.S. market, the company stated.

Quarterly sales of Allegra-D totaled $13.5 million for the 12 weeks ended Aug. 7, according to SymphonyIRI Group tabulating sales across food, drug and mass (minus Walmart) outlets.

July 25, 2011
ReportersNotebook — Chain Pharmacy, 8/1/11

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said.

SUPPLIER NEWS — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said. Janssen Pharmaceuticals announced the approval of Xarelto (rivaroxaban) tablets as a once-daily oral anticoagulant for DVT, a condition that could lead to pulmonary embolism.


July 15, 2011
FDA approves Dr. Reddy’s generic anticoagulant drug

The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.

HYDERABAD, India — The Food and Drug Administration has approved a generic anticoagulant drug made by Dr. Reddy’s Labs and Alchemia.

Dr. Reddy’s and Brisbane, Australia-based Alchemia announced the FDA approval of fondaparinux sodium injection in the 2.5 mg/0.5 mL, 5 mg/0.4 mL, 7.5 mg/0.6 mL and 10 mg/0.8 mL strengths. Alchemia owns the patents covering the process for synthesis of fondaparinux.

July 7, 2011
Dr. Reddy's generic Lotrel enters market

Dr. Reddy’s Labs has launched a generic drug for treating high blood pressure, the company said Thursday.

HYDERABAD, India — Dr. Reddy’s Labs has launched a generic drug for treating high blood pressure, the company said Thursday.

Dr. Reddy’s announced the launch of amlodipine besylate and benazepril hydrochloride capsules in the 5-mg/40-mg and 10-mg/40-mg strengths.

The drug is a generic version of Novartis’ Lotrel, which had sales of $290 million during the 12-month period ended in March, according to IMS Health.

June 22, 2011
Dr. Reddy's brings generic Levaquin to market

Generic drug maker Dr. Reddy’s Labs has launched its version of a popular antibiotic.

HYDERABAD, India — Generic drug maker Dr. Reddy’s Labs has launched its version of a popular antibiotic.

The company said its levofloxacin tablets in the 250-mg, 500-mg and 750-mg strengths have entered the market, following the Food and Drug Administration's approval of Dr. Reddy's abbreviated new drug application. Dr. Reddy's levofloxacin tablets in the 250-mg and 500-mg strengths are available in 50-count bottles, while the 750-mg strength bottle is available in 30-count bottles.

June 15, 2011
Dr. Reddy's subsidiary confirms receipt of FDA warning letter

The Food and Drug Administration has issued a warning letter to Dr. Reddy’s Labs’ chemical manufacturing plant in Mexico, the company said Tuesday.

HYDERABAD, India — The Food and Drug Administration has issued a warning letter to Dr. Reddy’s Labs’ chemical manufacturing plant in Mexico, the company said Tuesday.

The drug maker said Dr. Reddy’s subsidiary Industrias Quimicas Falcon de Mexico, in Cuernavaca, received an FDA warning letter based on a November 2010 inspection where the regulatory agency found a number of manufacturing problems.

Dr. Reddy’s said it takes the warnings seriously and will respond to the FDA and work with the agency to resolve the problems.

June 7, 2011
Dr. Reddy's gets OK for three drugs

Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

HYDERABAD, India — Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

The drug maker said that the FDA approved donepezil hydrochloride tablets, a generic version of Pfizer and Eisai's Arciept, in the 5-mg and 10-mg strengths for the treatment of Alzheimer's disease. Both strengths will be available in 30-, 90- and 500-count bottles.

April 25, 2011
Pozen, AstraZeneca file suit against Dr. Reddy's over generic Vimovo

A generic drug maker is being sued for patent infringement for its version of a fixed-dose combination drug co-created by Pozen and AstraZeneca.

CHAPEL HILL, N.C. — A generic drug maker is being sued for patent infringement for its version of a fixed-dose combination drug co-created by Pozen and AstraZeneca.

April 14, 2011
Dr. Reddy's announces market launch of generic OTC Allegra

The Food and Drug Administration has approved Dr. Reddy's version of an allergy medication that recently received Rx-to-OTC switch approval, the generic drug maker said.

HYDERABAD, India — The Food and Drug Administration has approved Dr. Reddy's version of an allergy medication that recently received Rx-to-OTC switch approval, the generic drug maker said.

Dr. Reddy's fexofenadine HCl tablets are bioequivalent versions of Sanofi-Aventis’ Allegra, which received Rx-to-OTC switch approval from the FDA in January.

The fexofenadine HCl Rx market had branded and generic sales of approximately $452 million for the 12 months ended last December, according to IMS Health.

March 30, 2011
Dr. Reddy's completes acquisition of U.S. penicillin facility, products from GSK

Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.

HYDERABAD, India — Dr. Reddy’s Labs will assume ownership of a penicillin manufacturing site in Bristol, Tenn., from GlaxoSmithKline.

The generic drug maker said it completed the acquisition of the facility and related product portfolio, including Augmentin and Amoxil brands. GSK will retain the existing rights for the aforementioned brands outside the United States.

Further financial terms and conditions of the transaction are not being disclosed.

March 29, 2011
Dr. Reddy's generic Xyzal hits market

Indian generic drug maker Dr. Reddy’s Labs has launched a generic treatment for seasonal allergies, the company said Tuesday.

HYDERABAD, India — Indian generic drug maker Dr. Reddy’s Labs has launched a generic treatment for seasonal allergies, the company said Tuesday.

Dr. Reddy’s announced the launch of levocetirizine tablets in the 5-mg strength. The drug is a generic version of UCB’s and Sanofi-Aventis’ Xyzal.

Levocetirizine had sales of about $238 million during the 12-month period ended in September 2010, according to IMS Health.

February 1, 2011
Dr. Reddy's gets OK to market generic allergy drug

A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.

HYDERABAD, India — A federal court has lifted an injunction that had prevented drug maker Dr. Reddy’s Labs from marketing a generic version of an allergy drug.

Dr. Reddy’s said the U.S. District Court of New Jersey had filed a stipulation and order lifting the earlier injunction against the drug maker regarding the selling of a version of fexofenadine hydrochloride and pseudoephedrine hydrochloride tablets in the 180-mg/240-mg strength. The drug is a generic version of Sanofi-Aventis’ and Albany Molecular Research’s Allegra-D 24.

January 21, 2011
Dr. Reddy's receives FDA approval for generic GERD treatment

Indian drug maker Dr. Reddy’s Labs has launched a generic treatment for gastroesophageal reflux disease.

HYDERABAD, India — Indian drug maker Dr. Reddy’s Labs has launched a generic treatment for gastroesophageal reflux disease.

The company announced Thursday the launch of pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths. The drug is a version of Protonix, made by Wyeth, now part of Pfizer.

Pantoprazole sodium delayed-release tablets had sales of around $1.8 billion during the 12-month period ended in September 2010, according to IMS Health.

November 21, 2010
Dr. Reddy’s launches generic Accolate

Indian generic drug maker Dr. Reddy’s Labs has launched a version of an asthma drug...

HYDERABAD, India Indian generic drug maker Dr. Reddy’s Labs has launched a version of an asthma drug for the U.S. market, the company said.

Dr. Reddy’s announced the launch of zafirlukast tablets in the 10-mg and 20-mg strengths. The drug is a version of AstraZeneca’s Accolate, which had sales of $50 million during the 12-month period ended in August, according to IMS Health.

October 18, 2010
Dr. Reddy's to launch generic Prevacid

Dr. Reddy's disclosed on Tuesday it will market a generic peptic ulcer treatment....

HYDERABAD, India Dr. Reddy's disclosed on Tuesday it will market a generic peptic ulcer treatment.

Dr. Reddy's lansoprazole delayed-release capsules will be available in 15-mg and 30-mg strengths, the drug maker said. The capsules are the generic version of Takeda's Prevacid delayed-release capsules.

The FDA approved Dr. Reddy’s abbreviated new drug application for the drug on Oct. 15.

August 8, 2010
Dr. Reddy's launches Cresp

Generic drug maker Dr. Reddy’s has launched in India the world’s first follow-on version of...

June 14, 2010
Injunction blocks Dr. Reddy's generic Allegra D24

A U.S. District Court has granted French drug maker Sanofi-Aventis and Albany Molecular Research an...